Wockhardt Launches Generic Prevacid

Wockhardt announced the launch of Lansoprazole Delayed-Release Capsules, the generic version of Takeda‘s Prevacid.

Lansoprazole, a proton pump inhibitor, is indicated in triple therapy or dual therapy for H. pylori eradication in duodenal ulcer disease, short-term treatment of active duodenal ulcer, active benign gastric ulcer, erosive esophagitis (EE), symptomatic GERD, and NSAID-associated gastric ulcers when NSAID use is continued, maintenance of healing of duodenal ulcer, EE, and long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome).

Lansoprazole is expected to launch immediately and will be available in 15mg and 30mg delayed-release capsules.

For more information call (800) 346-6854 or visit www.wockhardt.com.